Cyto-Mine® Chroma: Accelerating Single-Cell Analysis and Sorting using Multi-Laser Picodroplet Technology

Antibody therapeutics dominate drug development; however, lengthy workflows and rising costs in their discovery and development present significant challenges. Sphere Fluidics’ Cyto-Mine^® system leverages picodroplet technology, microfluidics, and imaging to overcome these hurdles in Antibody Discovery (AbD) and Cell Line Development (CLD), accelerating therapeutic development.

Here we introduce the next-generation Cyto-Mine® platform, Cyto-Mine^® Chroma. This advanced microfluidic platform, equipped with multi-laser, single-cell analysis capabilities, enables high-throughput, multiplex functional screening of millions of cells in a single day.

Our findings demonstrate that Cyto-Mine® Chroma can precisely sort and dispense cells based on fluorescence signals and sequential gating. Additionally, it achieves over 90% accuracy in isolating cells based on productivity and membrane dye from mixed populations. In an experiment simulating an AbD workflow, Cyto-Mine^® Chroma successfully isolated rare cells secreting antigen-specific antibodies with high precision.

Furthermore, by utilizing a viability dye alongside IgG-specific probes, we demonstrated its ability to isolate CHO cells producing human IgG4 based on both productivity and viability, without compromising cell performance. These results highlight Cyto-Mine^® Chroma’s robust multiplexing capabilities, making it an invaluable tool for isolating specific cell populations in both CLD and AbD workflows.